<DOC>
	<DOCNO>NCT00937040</DOCNO>
	<brief_summary>The purpose study compare ADHD symptom response adult ADHD treat OROS MPH treat placebo .</brief_summary>
	<brief_title>Adult Study / OROS Methylphenidate Hydrochloride ( HCL ) ( OROS MPH ) Adults With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>The hypothesis Osmotic Release Oral System ( OROS ) Extended Release Methylphenidate HCL ( OROS MPH ) safe effective improve Attention Deficit Hyperactivity Disorder ( ADHD ) symptoms adults ADHD compare placebo demonstrate use specific study measure . This double-blind ( neither participant investigator know name assign study drug ) , randomize ( study drug assign chance ) , placebo-controlled study evaluate efficacy safety OROS MPH use optimal dose adult patient study ADHD . The primary efficacy variable study change baseline final evaluation use Adult ADHD Investigator Symptom Rating Scale ( AISRS ) measure patient ADHD symptom . Participants also assess adverse event throughout study . Patients initiate treatment oral OROS MPH 18 mg match placebo baseline continue morning dosing increase every week optimal dose achieve , maximum 72 mg/day OROS MPH match placebo . Eligible patient remain study maximum 6 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Adults ADHD diagnosis ( type : Combined , Predominantly Inattentive , Predominantly HyperactiveImpulsive ) Patients Adult ADHD Investigator Symptom Rating Scale ( AISRS ) score great 24 screening/baseline Ability read understand English Any significant history cardiovascular disease cardiovascular disease detectable via ECG History diagnosis substance alcohol dependence admission/hospitalization rehabilitation dependence Current neurologic psychiatric diagnosis would make patient inappropriate participation Anxiety assessment moderate severe Depression assessment moderate severe History current suicidal thought attempt Known allergy , hypersensitivity , intolerance OROS MPH</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Osmotic Release Oral System ( OROS® ) Extended Release Methylphenidate HCl</keyword>
	<keyword>CONCERTA® ( OROS MPH )</keyword>
</DOC>